title: Successful combination therapy with trastuzumab and Paclitaxel for adriamycin- and docetaxel-resistant inflammatory breast cancer.
abstract: We present a case of adriamycin-and docetaxel-resistant inflammatory breast cancer (IBC) in which partial response was achieved with combination therapy using trastuzumab and paclitaxel. A 48-year old woman noticed a lump in her right breast. She was diagnosed with IBC and the disease was staged as T4d N1 M0, stage III B. The patient was started on neoadjuvant chemotherapy with adriamycin (50 mg/m2) and docetaxel (60 mg/m2) administered every three weeks. Six courses were performed and the response was evaluated as no change. After one month, contralateral breast swelling indicated bilateral IBC. Bilatera1 mastectomy using the Halsted method was performed. The immunohistochemical results of the Hercep Test was strongly positive (3+). After the mastectomy, right pleural effusion appeared, and cytological examination revealed the cells to be classV(adenocarcinoma). To treat the clinically advanced breast cancer, combination therapy with trastuzumab (initially 4 mg/kg followed by two or more cycles of 2 mg/kg) and paclitaxel (80 mg/m2) were given intravenously every week for eight cycles and then every two weeks thereafter. A total of 32 courses of therapy were performed, the pleural effusion completely disappeared and partial response was maintained for a duration of 482 days. The adverse reactions were mild, and it was possible for her to be treated as an outpatient with high quality of life. This report suggests that weekly combination therapy of trastuzumab and paclitaxel was useful for treatment of adriamycin-and docetaxel-resistant metastatic breast cancer.
authors.affiliation: Division of Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishishinbashi Minato-ku, Tokyo 105-846l, Japan. y-okawa@eurus.dti.ne.jp.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Okawa
authors.forename: Katsuki
authors.initials: K
authors.lastname: Sugiyama
authors.forename: Keisuke
authors.initials: K
authors.lastname: Aiba
authors.forename: Akio
authors.initials: A
authors.lastname: Hirano
authors.forename: Shinji
authors.initials: S
authors.lastname: Uno
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hagino
authors.forename: Kazumi
authors.initials: K
authors.lastname: Kawase
authors.forename: Hisashi
authors.initials: H
authors.lastname: Shioya
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yoshida
authors.forename: Noriko
authors.initials: N
authors.lastname: Usui
authors.forename: Masao
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kobayashi
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D016066:Pleural Effusion, Malignant / Q000209:etiology / Q000628:therapy; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D000068878:Trastuzumab; D017239:Paclitaxel